Back to Search
Start Over
Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.
- Source :
-
ImmunoHorizons [Immunohorizons] 2023 Oct 01; Vol. 7 (10), pp. 635-651. - Publication Year :
- 2023
-
Abstract
- Spike-encoding mRNA vaccines in early 2021 effectively reduced SARS-CoV-2-associated morbidity and mortality. New booster regimens were introduced due to successive waves of distinct viral variants. Therefore, people now have a diverse immune memory resulting from multiple SARS-CoV-2 Ag exposures, from infection to following vaccination. This level of community-wide immunity can induce immunological protection from SARS-CoV-2; however, questions about the trajectory of the adaptive immune responses and long-term immunity with respect to priming and repeated Ag exposure remain poorly explored. In this study, we examined the trajectory of adaptive immune responses following three doses of monovalent Pfizer BNT162b2 mRNA vaccination in immunologically naive and SARS-CoV-2 preimmune individuals without the occurrence of breakthrough infection. The IgG, B cell, and T cell Spike-specific responses were assessed in human blood samples collected at six time points between a moment before vaccination and up to 6 mo after the third immunization. Overall, the impact of repeated Spike exposures had a lower improvement on T cell frequency and longevity compared with IgG responses. Natural infection shaped the responses following the initial vaccination by significantly increasing neutralizing Abs and specific CD4+ T cell subsets (circulating T follicular helper, effector memory, and Th1-producing cells), but it had a small benefit at long-term immunity. At the end of the three-dose vaccination regimen, both SARS-CoV-2-naive and preimmune individuals had similar immune memory quality and quantity. This study provides insights into the durability of mRNA vaccine-induced immunological memory and the effects of preimmunity on long-term responses.<br /> (Copyright © 2023 The Authors.)
- Subjects :
- Humans
Immunoglobulin G immunology
SARS-CoV-2
Vaccines, Synthetic immunology
Immunogenicity, Vaccine immunology
Vaccine Efficacy
Immunization, Secondary
Lymphocyte Subsets immunology
BNT162 Vaccine immunology
BNT162 Vaccine therapeutic use
COVID-19 immunology
COVID-19 prevention & control
mRNA Vaccines immunology
Subjects
Details
- Language :
- English
- ISSN :
- 2573-7732
- Volume :
- 7
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- ImmunoHorizons
- Publication Type :
- Academic Journal
- Accession number :
- 37819998
- Full Text :
- https://doi.org/10.4049/immunohorizons.2300041